Heterogeneity of the resistance to gefitinib treatment in a non‐small cell lung cancer patient with active epidermal growth factor receptor mutation

por Xu, Chong‐Rui, Zhong, Wen‐Zhao, Zhou, Qing, Zhang, Xu‐Chao, Yang, Jin‐Ji, Wu, Yi‐Long
Publicado 2016

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

por Pi, Can, Xu, Chong‐Rui, Zhang, Ming‐feng, Peng, Xiao‐xiao, Wei, Xue‐wu, Gao, Xing, Yan, Hong‐Hong, Zhou, Qing
Publicado 2018

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

por Lu, Chang, Wei, Xue-Wu, Zhang, Yi-Chen, Chen, Zhi-Hong, Xu, Chong-Rui, Zheng, Ming-Ying, Yang, Jin-Ji, Zhang, Xu-Chao, Zhou, Qing
Publicado 2022

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations

por Wei, Xue-Wu, Deng, Jia-Yi, Xu, Chong-Rui, Chen, Zhi-Hong, Zhu, Dong-Qin, Wu, Qian, Zhang, Xu-Chao, Wu, Yi-Long, Zhou, Qing
Publicado 2022

Familial association of lung cancer with liver cancer in first-degree relatives

por Xu, Chong-Rui, Lin, Huan, Su, Jian, Zhang, Xu-Chao, Huang, Yi-Sheng, Yang, Xue-Ning, Zhou, Qing, Yang, Jin-Ji, Zhong, Wen-Zhao, Wu, Yi-Long
Publicado 2019

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-L...

por Wu, Yi-Long, Xu, Chong-Rui, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Shi, Jian Hua, Märten, Angela, Fan, Jean, Peil, Barbara, Zhou, Caicun
Publicado 2018

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

por Zhou, Qing, Yang, Jin-Ji, Chen, Zhi-Hong, Zhang, Xu-Chao, Yan, Hong-Hong, Xu, Chong-Rui, Su, Jian, Chen, Hua-Jun, Tu, Hai-Yan, Zhong, Wen-Zhao, Yang, Xue-Ning, Wu, Yi-Long
Publicado 2016

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

por Deng, Jia-Yi, Gou, Qing, Yang, Lingling, Chen, Zhi-Hong, Yang, Ming-Yi, Yang, Xiao-Rong, Yan, Hong-Hong, Wei, Xue-Wu, Liu, Jia-Qi, Su, Jian, Zhong, Wen-Zhao, Xu, Chong-Rui, Wu, Yi-Long, Zhou, Qing
Publicado 2023

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

por Zheng, Mei-Mei, Li, Yang-Si, Tu, Hai-Yan, Sun, Hao, Yin, Kai, Jiang, Ben-Yuan, Yang, Jin-Ji, Zhang, Xu-Chao, Zhou, Qing, Xu, Chong-Rui, Wang, Zhen, Chen, Hua-Jun, Zhou, De-Xiang, Wu, Yi-Long
Publicado 2022

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study

por Dong, Song, Zhao, Ning, Deng, Wei, Sun, Hui-wen, Niu, Fei-yu, Yang, Jin-ji, Zhong, Wen-zhao, Li, Feng, Yan, Hong-hong, Xu, Chong-rui, Zhang, Qiu-yi, Yang, Xue-ning, Liao, Ri-qiang, Nie, Qiang, Wu, Yi-long
Publicado 2017

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

por Gou, Lan-Ying, Li, An-Na, Yang, Jin-Ji, Zhang, Xu-Chao, Su, Jian, Yan, Hong-Hong, Xie, Zhi, Lou, Na-Na, Liu, Si-Yang, Dong, Zhong-Yi, Gao, Hong-Fei, Zhou, Qing, Zhong, Wen-Zhao, Xu, Chong-Rui, Wu, Yi-Long
Publicado 2016

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

por Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Publicado 2020

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

por Kang, Jin, Zhang, Xu-Chao, Chen, Hua-Jun, Zhong, Wen-Zhao, Xu, Yang, Su, Jian, Zhou, Qing, Tu, Hai-Yan, Wang, Zhen, Xu, Chong-Rui, Yang, Xue-Ning, Chen, Zhi-Hong, Wu, Xue, Zhang, Xian, Shao, Yang, Wu, Yi-Long, Yang, Jin-Ji
Publicado 2020

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

por Lou, Na-Na, Zhang, Xu-Chao, Chen, Hua-Jun, Zhou, Qing, Yan, Li-Xu, Xie, Zhi, Su, Jian, Chen, Zhi-Hong, Tu, Hai-Yan, Yan, Hong-Hong, Wang, Zhen, Xu, Chong-Rui, Jiang, Ben-Yuan, Wang, Bin-Chao, Bai, Xiao-Yan, Zhong, Wen-Zhao, Wu, Yi-Long, Yang, Jin-Ji
Publicado 2016

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I...

por Zhang, Yi-Chen, Chen, Zhi-Hong, Zhang, Xu-Chao, Xu, Chong-Rui, Yan, Hong-Hong, Xie, Zhi, Chuai, Shao-Kun, Ye, Jun-Yi, Han-Zhang, Han, Zhang, Zhou, Bai, Xiao-Yan, Su, Jian, Gan, Bin, Yang, Jin-Ji, Li, Wen-Feng, Tang, Wei, Luo, Feng Roger, Xu, Xiao, Wu, Yi-Long, Zhou, Qing
Publicado 2019

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

por Wang, Han-Min, Zhang, Chan-Yuan, Peng, Kai-Cheng, Chen, Ze-Xin, Su, Jun-Wei, Li, Yu-Fa, Li, Wen-Feng, Gao, Qing-Yun, Zhang, Shi-Ling, Chen, Yu-Qing, Zhou, Qing, Xu, Cong, Xu, Chong-Rui, Wang, Zhen, Su, Jian, Yan, Hong-Hong, Zhang, Xu-Chao, Chen, Hua-Jun, Wu, Yi-Long, Yang, Jin-Ji
Publicado 2023

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

por Tu, Hai‐Yan, Yin, Kai, Zhao, Xiaotian, Ke, E‐E, Wu, Si‐Pei, Li, Yang‐Si, Zheng, Mei‐Mei, Liu, Si‐Yang Maggie, Xu, Chong‐Rui, Sun, Yue‐Li, Lin, Jia‐Xin, Bai, Xiao‐Yan, Zhang, Yi‐Chen, Zhou, Qing, Yang, Jin‐Ji, Zhong, Wen‐Zhao, Wang, Bing‐Chao, Zhang, Xu‐Chao, Zhu, Dongqin, Yang, Lingling, Ou, Qiuxiang, Wu, Yi‐Long
Publicado 2023

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)

por Xu, Chong-Rui, Chen, Qixun, Zhou, Chengzhi, Wu, Lin, Li, Wen, Zhang, Huizhong, Li, Yongsheng, Xu, Fei, Xiong, Jianping, Wang, Qiming, Zhang, Haibo, Jiang, Yuequan, Yin, Haitao, Wu, Qingchen, Dai, Qiangsheng, Hu, Jian, Chen, Jianhua, Zhang, Jian, Wu, Gang, Yin, Jun, Zhao, Jianfu, Liu, Baogang, Shan, Jianzhen, Sheng, Liming, Chen, Qunqing, Han, Zhengxiang, Shi, Huaqiu, Liu, Yimin, Chen, Jun, Wu, Yi-Long
Publicado 2023

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8):...

por Maggie Liu, Si-Yang, Dong, Xiao-Rong, Wang, Zhen, Du, Yingying, Cui, Jiu-Wei, Chu, Qian, Xu, Bing-Fei, Zheng, Ming-Ying, Deng, Jia-Yi, Lu, Chang, Wei, Xue-Wu, Li, Yang-Si, Zheng, Mei-Mei, Yang, Ming-Yi, Huang, Jie, Li, Anna, Bai, Xiao-Yan, Sun, Yue-Li, Xu, Chong-Rui, Wang, Bin-Chao, Chen, Hua-Jun, Yang, Jin-Ji, Yan, Hong-Hong, Zhong, Wen-Zhao, Zhou, Qing, Wu, Yi-Long
Publicado 2023